Related Experiment Videos
Antischistosomal therapy: Current status and recent developments.
Gamal Esmat1, Maissa El Raziky1
1Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Summary
Praziquantel is the primary drug for schistosomiasis, but resistance is a growing concern. This review explores PZQ
Area of Science:
- Parasitology
- Tropical Medicine
- Drug Discovery
Background:
- Schistosomiasis is a widespread parasitic disease affecting millions globally.
- Praziquantel (PZQ) is the current cornerstone of mass drug administration for schistosomiasis.
- The extensive use of PZQ raises concerns about the potential evolution of drug resistance.
Discussion:
- This review examines the known mechanisms of action for Praziquantel.
- It assesses the likelihood and implications of developing Praziquantel resistance in Schistosoma parasites.
- Alternative therapeutic agents and novel schistosomicides are discussed.
Key Insights:
- Understanding PZQ's mechanism is crucial for predicting and combating resistance.
- Emerging drug resistance necessitates the exploration of alternative treatments.
- Vaccine development is a vital adjunct to chemotherapy for schistosomiasis control.
Outlook:
- Continued research into PZQ resistance mechanisms is essential.
- Development of novel schistosomicides is a priority for sustainable disease control.
- Integrating vaccines with chemotherapy offers a promising future strategy for schistosomiasis eradication.